Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EudraCT 2009-010364-42 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary aim of this study is to investigate the safety and tolerability of AZD2423 single doses in healthy volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental | AZD2423 |
|
| B | Experimental | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD2423 | Drug | oral, single administration |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the safety and tolerability of AZD2423 following administration of single ascending doses and if possible to estimate the maximum tolerated dose (MTD), if within the predefined exposure limits. | 3 day residential period plus 7-10 days follow up |
| Measure | Description | Time Frame |
|---|---|---|
| To characterise the pharmacokinetics of AZD2423 and provisionally assess the dose proportionality of the pharmacokinetics following administration of single ascending doses ofAZD2423. | 3 day residential period plus 7-10 days follow up |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rainard Fuhr, MD | PAREXEL Early Phase Clinical Uniit, Berlin Germany | Principal Investigator |
| Anders Neijber | AstraZeneca R&D Södertälje | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Berlin | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
oral administration and single dose |
|